Group items tagged

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

If you have asthma, it's important to know when you should see a doctor about an asthma flare-up. A flare-up is a sudden increase in your symptoms, which can include coughing, wheezing, chest tightness, and shortness of breath. Flare-ups can be mild or severe, and they can occur at any time. If you're not sure whether you're having a flare-up, here are six obvious signs that it might be time to see a doctor. 1. YOU'RE USING YOUR INHALER MORE THAN USUAL If you have asthma, you likely have a rescue inhaler that you use when you're having symptoms. This inhaler contains a medication that can quickly relieve your symptoms. If you find that you're using your rescue inhaler more often than usual, it could be a sign that your asthma is getting worse and you need to see a doctor. By seeking a doctor near me online, you can find a reputable physician who will accurately diagnose and treat your asthma. Always look for a second opinion, as one doctor's opinion might differ from others. For example, some doctors might recommend that you use a daily inhaler, while others might only recommend using it when you're having symptoms.

Several pharmacies have joined the inhaler recycling scheme in Wolverhampton, West Midlands, to support NHS England's Greener NHS programme, which aims to achieve net zero emissions by 2040. It is part of a collaborative working initiative between the Royal Wolverhampton NHS Trust and AstraZeneca UK Ltd, supported by the Black Country Integrated Care Board and Wolverhampton City Local Pharmaceutical Committee. Under this scheme, old and used inhalers are recycled and transformed into new products, such as coat hangers and waste bins. Simon Evans, group chief strategy officer for The Royal Wolverhampton NHS Trust, emphasised the importance of prioritising the reduction of carbon footprint while maintaining high-quality care, to protect the planet for future generations. "The Trust has already made significant achievements in several areas including the physical estate, clinical services, waste recycling, catering and medicines - with this inhaler recycling scheme from pharmacy being the latest string to our bow," he said.

Halothane is a time-tested inhalational anesthetic and is the gold standard for cost-effective induction and maintenance of anesthesia. It is manufactured by Piramal Critical Care in generic form for both human and veterinary use and is exported to 75 countries across the globe.

Piramal Critical Care is a business unit of Piramal Healthcare Limited. It manufactures and exports an extensive range of inhalation anesthetics like Sevoflurane, Halothane, Isoflurane and Enflurane, intravenous anesthetics like Propofol, regional anesthetics like Bupivacaine, muscle relaxants like Atracurium and plasma volume expanders like Polygeline.

Face masks can be quite discomforting to wear and there are a lot of reasons not to like them. You have to fiddle with the loops to wear them and after extended wear, they hurt. They also irritate your skin and fog up your glasses and make communication a little difficult. To foster mask adoption, the Department of Health and Human Services (HHS) in collaboration with the National Institute for Occupational Safety and Health (NIOSH) and the Biomedical Advanced Research and Development Authority, has launched a $500,000 "Mask Innovation Challenge" inviting Americans to submit ideas to make masks more comfortable to wear. The content is open until April 21 and participants have until then to submit innovative ideas that eliminate concerns with wearing masks while ensuring they are protecting themselves against coronavirus. In a press statement announcing the contest, Nikki Bratcher-Bowman, the acting assistant secretary for preparedness and response, said "with this mask challenge, we want to get people across the country involved in developing new masks that are both effective and comfortable. This will help us control COVID-19 and be better prepared for future public health emergencies." Contest Requirements and Prizes Anyone with a unique idea that follows CDC safety guidelines can submit their idea on or before 5 p.m ET on April 21. There are other requirements to enter and win this contest: 1. To receive a price, you must be a US citizen or a legal resident 2. For the first phase of the challenge, up to 10 winners will be chosen who will split a $100,000 prize, with each person taking $10,000 home. 3. Several parameters such as filtration efficiency, inhalation airflow resistance, fit, and other test methods will be used to judge the best design. According to HHS, sprays or drugs that can be inhaled or absorbed through the nose, mouth, or skin are not permitted to be used in mask design. NIOSH-approved respirators or FDA-approved surgical masks m

Olbas has announced the launch of its new TV ad campaign which will debut across the country this October. The TV campaign, which will be supported by a £1.5 million pound media investment, has been directed by commercial film director, Anthony Farquhar-Smith. The latest Olbas advertising creative will feature a new animated character, Lauren who is suffering with congestion caused by a cold. Lauren will be seen at home as the house begins to fill with balloons causing Lauren to feel uncomfortable and restricted, mimicking the 'bunged up' feeling of a heavy head cold. Olbas then saves the day as we see Lauren reach for a bottle of Olbas Oil to ease the symptoms of congestion, and as a result, the balloons deflate and the house returns to normal. Along with the large media investment, the campaign will also benefit from a strong PR programme to ensure the brand and retail sales are well supported throughout the peak cold and flu season. Owned by family-run health business, Lanes Health, Olbas Oil continues to be manufactured at their Gloucester based factory. Olbas uses only natural essential oils to provide a gentle but effective formulation to ease congestion and enhance breathing passages. The product offer includes Olbas Oil, Olbas For Children, Olbas Inhaler, Olbas Nasal Spray, Olbas Menthol Pastilles and Olbas Bath.

Piramal Critical Care manufactures generic and branded Enflurane (Compound 347) for Human use. Enflurane is the only modern Inhalation anesthetic approved for use in vaginal delivery. It is exported to various countries across the globe by Piramal Critical Care.

Isoflurane, USP is an inhalation anesthetic manufactured by Piramal Critical Care. It is used for induction and maintenance of general anesthesia in horses and dogs. Induction and recovery from anesthesia with isoflurane are rapid.

Manufactured by Piramal Critical Care, Sevoflurane is an inhalation anesthetic indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgeries. It is manufactured in generic and branded form (Sojourn and Petrem) for both human and veterinary use.

Generic & Branded Isoflurane (Terrell and Attane) manufactured by Piramal Critical Care are used as inhalation anesthetics for human & veterinary use. It is used in induction and maintenance of general anesthesia. It is exported to more than 100 countries across the globe by Piramal Critical Care.

Manufactured by Piramal Critical Care, Petrem (Sevoflurane) is an inhalation anesthetic indicated for induction and maintenance of general anesthesia in dogs. It is the first generic sevoflurane approved for veterinary use.

Asthmatic inhalers have proved to be quite effective and successful in helping people control their asthmatic symptoms and attacks. Read below to learn more about the medications that are available for treating asthma.

The first category is pulmonary tuberculosis, which allows bacteria to spread easily from an infected person to a healthy person who inhales the infected air because of an infected person's coughing or sneezing.

The findings of a recent study indicate the fact that commuters in California are likely inhaling chemicals at an increased level that might cause cancer or birth defects.

The Royal Pharmaceutical Society and Scottish Academy of Medical Royal Colleges co-hosted the NHS Education for Scotland annual virtual conference to discuss the environmental impact of prescribing. One of the conclusions drawn from the conference on Thursday (April 28) stressed on environmentally sustainable prescribing should be embedded in undergraduate and postgraduate health care education. Delegates at the session said they or their teams needed more education. They also needed more information and resources when prescribing to be able to consider environmental issues. Sharon Pfleger, Consultant in Pharmaceutical Public Health at NHS Highland, told the session: "There's a lot of work to be done to reduce carbon emissions. The NHS has identified the use of metered-dose inhalers as its second biggest cause of carbon emissions as the propellant gases have significant global warming potential.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors to start working on the quality criteria if they intend to meet the Respiratory domain of the Pharmacy Quality Scheme (PQS) 2022/23. For respiratory domain, community pharmacy contractors  must start working towards inhaler waste management; use of a spacer in patients aged 5-15 years; and personalised asthma action plans, from today (10 October). Resources are also available to support contractors with meeting the above criteria on the PQS hub page. PSNC also informed that contractors are also now able to make a claim for an Aspiration payment for the PQS 2022/23 on the NHS Business Services Authority (NHSBSA)  Manage Your Service (MYS) portal. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23.